

# Factsheet

## **Our Mission**

We use best-in-class enzyme engineering and production technologies to deliver superior biotech solutions enabling innovative industrial applications for partners in food and pharma.

## **Our Vision**

We want to develop c-LEcta into a recognized, global leader for high-performance enzymes promoting human health.

Metrics				
Revenue 2021	Employees	Clients	Patents	Majority
20 Mio. Euro	120+	400 +	100+	shareholder
				Kerry Group

## Management



**Dr. Marc Struhalla, CEO** More than 15 years of experience in the commercialisation of biotechnological industrial products




**Thomas Pfaadt, CFO** Expertise from management positions in corporate finance and investor relations in the healthcare sector



#### **Products**

c-LEcta supplies over 400 customers in more than 40 countries with biotechnologically manufactured quality products.

## **Applications**



#### **Technology**

c-LEcta uses its proprietary technology platform ENESYZ to develop customised enzymes and microbial production strains that meet the requirements of a wide range of manufacturing processes in industry. It has been continuously developed since its foundation in 2004. In the last 18 years, we have carried out more than 50 enzyme engineering projects with a success rate of >90%.

### Why work with c-LEcta?



We meet the highest quality requirements of our customers in the pharmaceutical and food industries throughout the entire product life cycle. c-LEcta works in collaborations with industry partners to jointly develop new products and bring them to market.





As one of the leading technology companies for products manufactured by fermentation, c-LEcta also offers its skills to the industry as a production partner.